KKR Provides $170MM Term Loan to Aimmune Therapeutics
An affiliate of KKR signed a $170 million term loan agreement with Aimmune Therapeutics, a biopharmaceutical company developing treatments for potentially life-threatening food allergies.
January 7, 2019
Aimmune Therapeutics | Emily Janvey | KKR
Amanda Koprowski